<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39374592</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1449-8944</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Australian health review : a publication of the Australian Hospital Association</Title><ISOAbbreviation>Aust Health Rev</ISOAbbreviation></Journal><ArticleTitle>Feasibility of an allied health led, workplace delivered Long COVID service for hospital staff: a mixed-methods study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1071/AH24146</ELocationID><Abstract><AbstractText>ObjectiveThis study aimed to evaluate the feasibility of a workplace-delivered outpatient multidisciplinary service (ReCOV) for staff experiencing post COVID-19 condition ('Long COVID').MethodsA mixed-methods study of staff at a large, tertiary hospital with Long COVID who attended the service was conducted. Participants completed questionnaires to determine baseline symptoms and were offered allied health appointments for up to 12weeks each based on clinical indication. Acceptability, implementation, practicality and limited efficacy were evaluated via one-on-one semi-structured interviews and analysed using inductive thematic analysis. Limited efficacy was evaluated via pre- and post-questionnaires and demand via multidisciplinary utilisation.ResultsTwenty-three (median age 37 [interquartile range 30-45] years, 52% female) participants were included. Participants had appointments with a median of 4 [3-5] different professions; most commonly exercise physiology (n=19, 83%), occupational therapy (n=17, 74%) and neuropsychology (n=15, 65%). Median time spent on the ReCOV service was 15 [9-19] weeks. Thirteen semi-structured interviews were completed and analysed. Participants valued ReCOV for being a COVID-19 specific, convenient, flexible and multidisciplinary service at their workplace. Participants preferred the service to have been available for longer than 12weeks to achieve further benefits as many participants perceived little change in physical health.ConclusionsAttending a multidisciplinary service located at their workplace was feasible for staff to manage post COVID-19 symptoms. Further research is required to confirm the efficacy on patient outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D'Souza</LastName><ForeName>Aruska N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>Granger</LastName><ForeName>Catherine L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Calulo Rivera</LastName><ForeName>Zoe</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Aisling</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ngwenya</LastName><ForeName>Riley</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Struck</LastName><ForeName>Carly</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Merrett</LastName><ForeName>Myvanwy</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fazio</LastName><ForeName>Timothy N</ForeName><Initials>TN</Initials></Author><Author ValidYN="Y"><LastName>Juj</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Peiris</LastName><ForeName>Casey L</ForeName><Initials>CL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Aust Health Rev</MedlineTA><NlmUniqueID>8214381</NlmUniqueID><ISSNLinking>0156-5788</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39374592</ArticleId><ArticleId IdType="doi">10.1071/AH24146</ArticleId><ArticleId IdType="pii">AH24146</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>